老年人肺炎球菌疫苗接种的经济学证据：不确定的建模还是竞争性招标？ - Suppr

Suppr

超能文献

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

作者信息

Garattini Livio, Padula Anna, Da Costa Milene Rangel

机构信息

IRCCS Institute for Pharmacological Research "Mario Negri", 24020, Ranica, Italy.

Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Pharmacoeconomics. 2016 Mar;34(3):221-4. doi: 10.1007/s40273-015-0341-4.

DOI:10.1007/s40273-015-0341-4

PMID:26518294

Abstract

摘要

相似文献

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?老年人肺炎球菌疫苗接种的经济学证据：不确定的建模还是竞争性招标？

Pharmacoeconomics. 2016 Mar;34(3):221-4. doi: 10.1007/s40273-015-0341-4.

Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.在英国为老年人和高危成年人接种23价肺炎球菌多糖疫苗或13价肺炎球菌结合疫苗的成本效益

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27. doi: 10.1586/14737167.2014.950232. Epub 2014 Sep 5.

[Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].[针对患有潜在临床疾病风险的成年人肺炎球菌疫苗接种的共识文件]

Rev Esp Quimioter. 2013 Sep;26(3):232-52.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.克罗地亚肺炎球菌结合疫苗接种的成本效益

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.在英国，对老年人和高危成年人接种23价肺炎球菌多糖疫苗或13价肺炎球菌结合疫苗的公共卫生及预算影响分析。

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):901-11. doi: 10.1586/14737167.2014.953932. Epub 2014 Sep 4.

Challenges in cost-effectiveness analyses of hospital interventions to improve quality.医院干预措施改善质量的成本效益分析中的挑战。

Infect Control Hosp Epidemiol. 2008 May;29(5):395-7. doi: 10.1086/587966.

Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results.成人肺炎球菌疫苗接种策略的经济学评估。结果总结。

Acta Clin Belg. 2005 Nov-Dec;60(6):338-44. doi: 10.1179/acb.2005.051.

Pneumococcal Vaccines--a Real World Perspective.肺炎球菌疫苗——真实世界视角

J Assoc Physicians India. 2015 Apr;63(4 Suppl):25-8.

[Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].[老年人肺炎球菌血症疫苗接种的成本效益：比利时的结果]

Acta Clin Belg. 2000 Sep-Oct;55(5):257-65.

Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.老年人接种疫苗预防侵袭性肺炎球菌感染的药物经济学：成本效益分析及对荷兰的启示

Expert Rev Vaccines. 2003 Aug;2(4):477-82. doi: 10.1586/14760584.2.4.477.

引用本文的文献

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.肺炎与侵袭性肺炎球菌疾病：肺炎球菌结合疫苗在多重耐药时代的作用

Vaccines (Basel). 2021 Apr 22;9(5):420. doi: 10.3390/vaccines9050420.

本文引用的文献

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.荷兰成人肺炎球菌结合疫苗接种的成本效益

Eur Respir J. 2015 Nov;46(5):1407-16. doi: 10.1183/13993003.00325-2015. Epub 2015 Jul 9.

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly.13价肺炎球菌结合疫苗（PCV13）在成人和老年人中的经济评估综述。

Hum Vaccin Immunother. 2015;11(4):818-25. doi: 10.1080/21645515.2015.1011954.

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.多糖结合疫苗预防成人肺炎球菌性肺炎。

N Engl J Med. 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27. doi: 10.1586/14737167.2014.950232. Epub 2014 Sep 5.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):901-11. doi: 10.1586/14737167.2014.953932. Epub 2014 Sep 4.

Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.预防老年人非菌血症性肺炎球菌肺炎：历史背景及在13价肺炎球菌结合疫苗（PCV13）和23价肺炎球菌多糖疫苗（PPV23）之间进行选择的考量

Hum Vaccin Immunother. 2014;10(5):1322-30. doi: 10.4161/hv.28797. Epub 2014 Apr 14.

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.23 价肺炎球菌多糖疫苗对 60 岁以上普通人群社区获得性肺炎的有效性：CAPAMIS 研究 3 年随访结果。

Clin Infect Dis. 2014 Apr;58(7):909-17. doi: 10.1093/cid/ciu002. Epub 2014 Feb 13.

Determining the cost-effectiveness of adult pneumococcal vaccination strategies.评估成人肺炎球菌疫苗接种策略的成本效益。

Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):1-4. doi: 10.1586/14737167.2014.868312. Epub 2013 Dec 16.

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.新型肺炎球菌疫苗的成本效益：欧洲研究的系统评价。

Pharmacoeconomics. 2014 Jan;32(1):29-45. doi: 10.1007/s40273-013-0113-y.

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.意大利南部坎帕尼亚地区成人接种13价肺炎球菌疫苗的经济学评估

Hum Vaccin Immunother. 2014;10(2):492-7. doi: 10.4161/hv.26888. Epub 2013 Nov 1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验